Safety and Efficacy of CPX-351 in Younger Patients < 60 Years Old with Secondary Acute Myeloid Leukemia: An Updated Analysis

被引：4

作者：

Przespolewski, Amanda ^{[1
]}

Goldberg, Aaron D. ^{[2
]}

Talati, Chetasi ^{[3
]}

Fazal, Salman ^{[4
]}

Vachhani, Pankit ^{[5
]}

Sanikommu, Srinivasa Reddy R. ^{[6
]}

Thota, Swapna ^{[7
]}

Waksal, Julian ^{[8
]}

Ball, Brian ^{[8
,9
]}

Famulare, Christopher ^{[10
]}

Stahl, Maximilian ^{[11
]}

Mckinnell, Zoe ^{[9
]}

Baron, Jeffrey ^{[12
]}

Griffiths, Elizabeth A. ^{[13
,14
]}

Thompson, James E. ^{[15
]}

Sweet, Kendra

Wang, Eunice S. ^{[1
]}

机构：

[1] Roswell Pk Comprehens Canc Ctr, Dept Med, Leukemia Serv, Buffalo, NY USA

[2] Mem Sloan Kettering Canc Ctr, Dept Med, Leukemia Serv, New York, NY USA

[3] H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL USA

[4] Allegheny Hlth Network Canc Inst, Pittsburgh, PA USA

[5] Univ Alabama Birmingham, ONeal Comprehens Canc Ctr, Birmingham, AL USA

[6] Levine Canc Inst, Dept Hematol Oncol & Blood Disorders, Atrium Hlth, Charlotte, NC USA

[7] Univ Tennessee, St Jude Res Hosp, Hlth Sci Ctr, Memphis, TN USA

[8] Mem Sloan Kettering Canc Ctr, New York, NY USA

[9] City Hope Natl Med Ctr, Duarte, CA USA

[10] Mem Sloan Kettering Canc Ctr, Dept Med, Leukemia Serv, New York, NY USA

[11] Roswell Pk Comprehens Canc Ctr, Dept Pharm, Buffalo, NY USA

[12] Roswell Pk Comprehens Canc Ctr, Div Hematol, Dept Internal Med, Buffalo, NY USA

[13] Roswell Pk Comprehens Canc Ctr, Dept Med, Leukemia Serv, Buffalo, NY USA

[14] Roswell Pk Comprehens Canc Ctr, Buffalo, NY USA

[15] H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL USA

来源：

BLOOD | 2021年 / 138卷

关键词：

D O I：

10.1182/blood-2021-153791

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1264

引用

页数：5

共 50 条

[41] TP53 Mutations Predict Poorer Responses to CPX-351 in Acute Myeloid Leukemia
Goldberg, Aaron D.
Talati, Chetasi
Desai, Pinkal
Famulare, Christopher
Devlin, Sean M.
Farnoud, Noushin
Sallman, David A.
Lancet, Jeffrey E.
Roboz, Gail J.
Sweet, Kendra L.
Tallman, Martin S.
[J]. BLOOD, 2018, 132
[42] Consolidation outcomes in CPX-351 versus cytarabine/daunorubicin-treated older patients with high-risk/secondary acute myeloid leukemia
Kolitz, Jonathan E.
Strickland, Stephen A.
Cortes, Jorge E.
Hogge, Donna
Lancet, Jeffrey E.
Goldberg, Stuart L.
Villa, Kathleen F.
Ryan, Robert J.
Chiarella, Michael
Louie, Arthur C.
Ritchie, Ellen K.
Stuart, Robert K.
[J]. LEUKEMIA & LYMPHOMA, 2020, 61 (03) : 631 - 640
[43] PRELIMINARY DATA OF CPX-351 TREATMENT IN A MULTI-CENTER REAL-LIFE EXPERIENCE IN YOUNG PATIENTS (<60 YEARS OLD) AFFECTED BY THERAPHY RELATED ACUTE MYELOID LEUKEMIA AND ACUTE MYELOID LEUKEMIA WITH MYELODYSPLASIA-RELATED CHANGES
Garibaldi, B.
Brunetti, L.
Vigna, E.
Mauro, E.
Maugeri, C.
Parisi, M. S.
Fiumara, P. F.
Duminuco, A.
Martino, E.
Mazzantini, E.
Galimberti, S.
Gentile, M.
Palumbo, G. A.
Di Raimondo, F.
Vetro, C.
[J]. HAEMATOLOGICA, 2021, 106 (10) : 133 - 134
[44] Healthcare resource utilization in a phase 3 study of CPX-351 in patients with newly diagnosed high-risk/secondary acute myeloid leukemia
Villa, Kathleen F.
Ryan, Robert J.
Chiarella, Michael
Louie, Arthur C.
[J]. JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (07) : 714 - 720
[45] CPX-351 Treatment for Acute Myeloid Leukaemia in England: Real-world Outcomes in Adults Aged <60 Years
Legg, Alex
Reich, Adam
Wilkes, Emily
Medalla, Greg
[J]. BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 : 59 - 60
[46] A Two-Part Study Evaluating the Combination of Tazemetostat and CPX-351 ( Part 1) and Palbociclib with CPX-351 (Part 2) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
Keiffer, Gina
Calabretta, Bruno
Mazo, Alexander
Outschoorn, Ubaldo Martinez
Alpdogan, Onder
Binder, Adam F.
Porcu, Pierluigi
Wilde, Lindsay
Kasner, Margaret
[J]. BLOOD, 2023, 142
[47] Phase 2 Study of CPX-351 in Combination with Venetoclax in Patients with Newly Diagnosed, High Risk Acute Myeloid Leukemia
Jen, Wei-Ying
DiNardo, Courtney D.
Chien, Kelly S.
Alvarado-Valero, Yesid
Masarova, Lucia
Brandt, Mark
Bull-Linderman, Debra
Daver, Naval
Montalban-Bravo, Guillermo
Bataller, Alex
Garcia-Manero, Guillermo
Issa, Ghayas C.
Alousi, Amin
Short, Nicholas J.
Ravandi, Farhad
Kadia, Tapan M.
[J]. BLOOD, 2023, 142
[48] Real-World Experience of CPX-351 As First-Line Treatment in 188 Patients with Acute Myeloid Leukemia
Rautenberg, Christina
Stoelzel, Friedrich
Roellig, Christoph
Stelljes, Matthias
Gaidzik, Verena
Lauseker, Michael
Kriege, Oliver
Verbee, Mareike
Unglaub, Julia Marie
Thol, Felicitas
Krause, Stefan W.
Haenel, Mathias
Neuerburg, Charlotte
Vucinic, Vladan
Jehn, Christian-Friedrich
Severmann, Julia
Wass, Maxi
Fransecky, Lars
Chemnitz, Jens
Holtick, Udo
Schaefer-Eckart, Kerstin
Schroeder, Josephine
Kraus, Sabrina
Krueger, William
Kaiser, Ulrich
Scholl, Sebastian
Koch, Kathrin
Henning, Lea
Kobbe, Guido
Haas, Rainer
Alakel, Nael
Roehnert, Maximilian-Alexander
Sockel, Katja
Hanoun, Maher
Platzbecker, Uwe
Holderried, Tobias A. W.
Morgner, Anke
Heuser, Michael
Sauer, Tim
Goetze, Katharina S.
Wagner-Drouet, Eva
Doehne, Konstanze
Doehner, Hartmut
Schliemann, Christoph
Schetelig, Johannes
Bornhaeuser, Martin
Germing, Ulrich
Schroeder, Thomas
Middeke, Jan Moritz
[J]. BLOOD, 2021, 138
[49] CPX-351 versus 7+3 in acute myeloid leukemia of the elderly patient: advantage in overall survival at five years
Saillant, Arnaud
Moya, Niels
Leleu, Xavier
[J]. HEMATOLOGIE, 2021, 27 (05): : 216 - +
[50] Cardiotoxicity of CPX-351 vs 7+3 in patients with untreated high-risk acute myeloid leukemia
Mitchell, Joshua
Pfeiffer, Michael
Boehmer, John
Gorcsan, John
Dronamraju, Nalina
Faderl, Stefan
Lin, Tara L.
Uy, Geoffrey L.
Lancet, Jeffrey E.
Cortes, Jorge E.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)

← 1 2 3 4 5 →